LifeCycle Pharma terminates contract agreement with CEO

LifeCycle Pharma A/S (OMX: LCP) announced today that the Board of Directors of LCP and Jim New have agreed to terminate the contract with Jim New. Hence, Jim New will with immediate effect step down as the President and CEO of LCP. The termination is related to different views on how an international company based in Scandinavia shall be managed.

The Board of Directors will immediately commence the search for a new CEO. Until a new CEO has been identified, Paul Edick, Chairman of the Board of LCP, and Dr. Thomas Dyrberg, constituted Deputy Chairman of the Board, will, upon request from the Board of Directors, assume such specific assignments for the Company, which are necessary to ensure LCP's continual and uninterrupted business together with the management of LCP.

http://www.lcpharma.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.